Michael Sigouros
Overview
Explore the profile of Michael Sigouros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1033
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Mendelson N, Al Assaad M, Hadi K, Manohar J, Sigouros M, Sboner A, et al.
Am J Surg Pathol
. 2023 Jul;
47(10):1192-1193.
PMID: 37489101
No abstract available.
22.
Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed A, Bareja R, et al.
Clin Cancer Res
. 2023 May;
29(15):2933-2943.
PMID: 37223924
Purpose: Patients with neuroendocrine prostate cancer (NEPC) are often managed with immunotherapy regimens extrapolated from small-cell lung cancer (SCLC). We sought to evaluate the tumor immune landscape of NEPC compared...
23.
Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al.
Blood
. 2023 Feb;
141(18):2194-2205.
PMID: 36796016
Peripheral T-cell lymphomas (PTCL) with T-follicular helper phenotype (PTCL-TFH) has recurrent mutations affecting epigenetic regulators, which may contribute to aberrant DNA methylation and chemoresistance. This phase 2 study evaluated oral...
24.
Sternberg C, Shin N, Chernyshov K, Calabro F, Cerbone L, Procopio G, et al.
Front Oncol
. 2022 Nov;
12:1006017.
PMID: 36387205
Although immune checkpoint inhibitors (ICIs) are increasingly used as second-line treatments for urothelial cancer (UC), only a small proportion of patients respond. Therefore, understanding the mechanisms of response to ICIs...
25.
Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, et al.
NAR Cancer
. 2022 Jun;
4(2):zcac016.
PMID: 35664542
Sequencing of cell-free DNA (cfDNA) in cancer patients' plasma offers a minimally-invasive solution to detect tumor cell genomic alterations to aid real-time clinical decision-making. The reliability of copy number detection...
26.
Brendel M, Getseva V, Al Assaad M, Sigouros M, Sigaras A, Kane T, et al.
EBioMedicine
. 2022 Jun;
80:104067.
PMID: 35644123
Background: Estimating tumor purity is especially important in the age of precision medicine. Purity estimates have been shown to be critical for correction of tumor sequencing results, and higher purity...
27.
Alnajar H, Ravichandran H, Rendeiro A, Ohara K, Al Zoughbi W, Manohar J, et al.
Cold Spring Harb Mol Case Stud
. 2022 Apr;
8(3).
PMID: 35483877
Sarcomatoid urothelial carcinoma (SUC) is a rare subtype of urothelial carcinoma (UC) that typically presents at an advanced stage compared to more common variants of UC. Locally advanced and metastatic...
28.
Berchuck J, Baca S, McClure H, Korthauer K, Tsai H, Nuzzo P, et al.
Clin Cancer Res
. 2021 Dec;
28(5):928-938.
PMID: 34907080
Purpose: Neuroendocrine prostate cancer (NEPC) is a resistance phenotype that emerges in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has important clinical implications, but is challenging to detect in...
29.
Mosquera M, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al.
Adv Mater
. 2021 Oct;
34(2):e2100096.
PMID: 34676924
Following treatment with androgen receptor (AR) pathway inhibitors, ≈20% of prostate cancer patients progress by shedding their AR-dependence. These tumors undergo epigenetic reprogramming turning castration-resistant prostate cancer adenocarcinoma (CRPC-Adeno) into...
30.
Conteduca V, Ku S, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, et al.
NPJ Precis Oncol
. 2021 Sep;
5(1):84.
PMID: 34518634
No abstract available.